MST3-IN-1 (TFA)
MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 TFA shows antiproliferative activity against HepG2 cell. MST3-IN-1 TFA effectively induces Apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 TFA significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 TFA can be used for the study of liver cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family; Caspase; Hippo (MST)
Related Pathways
Apoptosis; Stem Cell/Wnt
Field of Research
Cancer
Purity
99.38
Smiles
O=C(C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(C=C3C1=O)F)NC5=NC6=C(S5)C=C(OC(F)(F)F)C=C6.OC(C(F)(F)F)=O
Molecular Formula
C27H22F7N5O5S
Molecular Weight
661.55
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45 / LCA (2B11 + PD7/26), CF640R conjugate, 0.1mg/mL
CD63 (MX-49.129.5), CF640R conjugate, 0.1mg/mL
Bcl-2 (Apoptosis & Follicular Lymphoma Marker) (rBCL2/782), CF488A conjugate, 0.1mg/mL
P53 Tumor Suppressor Protein (TP53/1739), CF488A conjugate, 0.1mg/mL
